interferences from macro CK-1 or mitochondrial CK (macro CK-2) have been described for several of these methods (7-9).
ference in samples with very high concentrations of CK-BB (14) (15) (16) (17) . In addition, several immunoassays are prone to interference from antibodies in human serum directed against immunoglobulin from the species used to produce the specific antiserum (18). Recently, monoclonal antibodies specific for CK-MB have been developed (19) (20) (21) . In one application, a CK-MBspecific monoclonal antibody is used for immunocapture of CK-MB, followed by measurement of the isoenzyme's catalytic activity (20) . This assay has been in routine clinical use at our institutions for more than two years and has performed well.
More recently, commercial inimunometric assays have been described that measure CK-MB mass by utilizing a CK-MB-specific monoclonal antibody in conjunction with a CK-BB-specific monoclonal antibody. One of these, the Stratus CK-MB assay, utilizes the identical CK-MB-specific monoclonal antibody as our immunocapture/activity assay, thereby providing a unique opportunity to directly compare measurements of enzyme mass and activity. Because the Stratus assay also offers the ability to measure CK-MB rapidly and has "stat" capabilities, we evaluated the analytical performance of this assay and compared it with that of the immunocapture/activity assay.
Materials and Methods
Clinical specimens. Initial evaluation of the Stratus assay involved 623 specimens received for routine CK-MB determinations by the clinical chemistry laboratory at Barnes Hospital during an eight-week period and 183 serum samples from the cardiac care unit received by the clinical chemistry laboratory at Jewish Hospital. Serum samples at Barnes Hospital were supplemented with ,8-mercaptoethanol (final concentration, 15 mmolJL) before analysis; no sample pretreatment was used at Jewish Hospital. For subsequent studies we selected clinical sam plea on the basis of increased values of either CK-MB or alkaline phosphastase (EC 3.1.3.1).
CK-MB
assays. The "Conan" immunocapture assay specifically measures CK-MB enzymatic activity as previously described (20). To a bead coated with anti-MB-specific monoclonal antibody ("Conan-MB"), add 100 1.iLof serum and 10 L of 0.2 mol/L f3-mercaptoethanol and incubate for 1 h at room temperature.
After washing, incubate the beads with 250 pL of CK reagent for 45 mm at 37 #{176}C. absorbance at 492 nm after allowing color development for 5 mm. The Stratus CK-MB assay (Baxter Healthcare Corp., Miami, FL) is an automated fluorometric enzyme immunoassay that measures CK-MB mass concentration; we used it according to the manufacturer's instructions. Briefly, 60 L of serum is automatically added to a tab coated with the same CK-MB-specific monoclonal antibody as is used in the Conan assay. After a brief incubation period, the Fab fragment of a CK-BB-specific monoclonal antibody conjugated to alkaline phosphatase is added, followed by a substrate/wash solution of methylumbelliferyl phosphate in a diethanolamine buffer (pH 9.0). The reaction rate is monitored by front-surface fluorescence, which varies directly with the concentration of CK-MB. Fluorescence of an unknown sample is compared with that of CK-MB standards.
The assay is complete in -8 mm. Linearity, sensitivity, and precision. Linearity and sensitivity of the Stratus CK-MB assay was determined by adding affinity-purified CK-MB (22) to the heat-inactivated human serum pool to yield a CK-MB concentration of 140 gfL. Individual dilutions were then prepared with the heat-inactivated serum pool. Intra-and interassay precision was determined by using repeated assays of patients' samples having CK-MB values between 7 and 16 ug/L and Stratus CK-MB quality-control material at three different concentrations.
Statistical analysis. Data comparing the Conan and Stratus CK-MB assays were analyzed by unweighted linearregression analysis.
Results

Stratus Assay Performance
The assay demonstrated linearity beyond the highest standard (118 ug/L) provided by the manufacturer for the lot of reagents in use at the time of evaluation. The sensitivity (lower detection limit) of the Stratus CK-MB assay was determined to be -2 g/L by measuring individual dilutions with heat-inactivated serum of a serum pool having an assayed CK-MB value of 10.7 ig/L; this limit was confirmed in assays of dilutions of a heat-inactivated serum pool to which affinity-purified CK-MB was added. Therefore, we routinely report low values as <2 g/L, which is more than adequate for clinical use.
Intra-assay precision (CV) assays of four patients' samples with CK-MB values between 6 and 14 ig/L was determined by assaying each sample six times; results ranged from 2.3% to 3.1% ( ,ttg/L were each assayed six times (Intra-assay)during a single Stratus run, or for seven consecutIve days (Interassay). b Three concentrations of Stratus quality-controlmaterial with mean CK-MBvalues between 9.3 and83.9 g/t. were assayed over a 95-day period of routine clinical runs. 
4.45).
Repeat measurements
of statistical outliers (>2 SD from the regression line) gave similar results 90% of the time for both assays. Discrepancies appeared with equal frequency for each assay for samples that gave different values on repeat analysis. Of the 417 samples outside the analytical ranges, none was considered to give a false-positive or false-negative result [assuming an upper reference limit of <12 UIL by the Conan assay (20) and the equivalent of <7.5 pgfL by the Stratus assay, based on our correlation].
At Jewish Hospital an additional 183 samples from patients in the cardiac care unit at that hospital were examined.
Eighty-eight samples had values within the analytical range of both assays. This patient population yielded the following relationship: Stratus = O.54(Conan) + 1.17 (r = 0.93). Of the 95 samples excluded from regression analysis, a single sample was considered to have a falsely increased result in the Stratus assay.
Falsely Increased Stratus Values for CK-MB
During our initial evaluation the one false-positive sample had a Stratus value of 13.5 g/L and a negative value (<4 UIL) by the Conan assay. This sample was also negative for CK-MB by electrophoresis. To investigate the cause of the false-positive value, we tested this sample in the Stratus CK-MB assay system with a thyrotropin (TSH)
antibody-coated
Stratus tab instead of the anti-CK-MBcoated tab. Surprisingly, the sample gave a CK-MB value of 14.4 tg/L, although, as expected, other samples with CK-MB values between 2 and 13 ,ug/L were consistently <2 g/L when assayed with TSH tabs in the Stratus CK-MB assay system. Examination of this patient's medical record revealed alkaline phosphatase values >1100 UIL during the period the CK-MB sample was collected. Therefore, we examined samples from 23 patients selected for alkaline phosphatase values >460 UIL, using tabs coated with some irrelevant antibody. Under these conditions, samples from 12 of the 23 selected patients gave falsely increased CK-MB values (CK-MB 3 &gfL) ( Table 2) .
Consequently, using TSH antibody-coated tabs, we began screening all samples received for routine CK-MB analysis for which the Stratus CK-MB value was >6 tg/L. During a 10-week period we identified 46 of 5270 routine CK-MB samples received by the laboratory (<0.9% of all samples) to be falsely increased for CK-MB when TSH tabs were substituted in the Stratus CK-MB assay system. These samples were from 23 of the 1933 patients (1.2% of patients) for whom CK-MB was assayed during this time (Table 3 ). The increase for 14(0.7%) of these patients (A-N, Table 3 ) was clinically significant (Stratus 7 g/L; Conan <12 UIL). We observed additional falsely increased Stratus C Notdone values that were probably not clinically significant (pa tients O-T). Patients U and V gave normal values in be assays, despite the false signal on the irrelevant antibod tab.
Because high-molecular-mass forms of alkaline phospha tase are often present in the serum of patients with chol static liver disease (23-25), we investigated whether th discordant results were related to these forms of endog nous alkaline phosphatase.
Sepharose chromatography o 1.5 mL of serum from a patient that gave a falsely increased Stratus CK-MB result revealed two peaks of alkaline phosphatase activity (Table 4 ). In contrast, only the low-molecular-mass fraction (150-200 kDa) was present i a sample without discordant Stratus CK-MB values. Addition of the high-molecular-mass fraction to normal serum yielded falsely increased Stratus CK-MB values and CK-MB values >3 tg/L on TSH tabs, indicating that this fraction was a cause of the discordant CK-MB results.
Interestingly, treatment of this fraction with phospholipase C (EC 3.1.4.3) eliminated 80% of the falsely increased CK-MB signal but did not alter its alkaline phosphatase activity. This strongly suggested that the interfering highmolecular-mass alkaline phosphatase was associated with cell membrane fragments, the alkaline phosphatase being anchored to the membrane via a phosphatidylinositol linkage (28) . Furthermore, the interference from the highmolecular-mass form of alkaline phosphatase (a) was not associated with immunoglobulin (29) , (b) was associated with other membrane-bound enzymes, and (c) was associated with an electrophoretic band of alkaline phosphatase that was anodal to the liver fraction. Three additional samples producing falsely increased Stratus CK-MB values also demonstrated this anodal band, whereas samples not producing discordant Stratus CK-MB values did not. Interestingly, treatment of the high-molecular-mass fraction with phospholipase C shifted the peak for alkaline phosphatase activity to an electrophoretic mobility consistent with liver alkaline phosphatase.
Taken together, we conclude that membrane-fragment-associated high-molecularmass alkaline phosphatase is a cause of the false increase in Stratus CK-MB values.
However, not all samples with a high-molecular-mass form(s) of alkaline phosphatase resulted in discordant Stratus CK-MB values. Four of the samples selected for increased alkaline phosphatase activity (see Table 2 ) were examined by sodium dodecyl sulfate-.polyacrylainide gel electrophoresis by Dr. E. Epstein, Royal Oak, MI (30). Two samples that produced falsely increased CK-MB values (samples 3 and 11, Table 2), and two that did not, demon. strated the presence of a high-molecular-mass form of alkaline phosphatase by this method.
Elimination of Falsely Increased Stratus CK-MB Values
To eliminate falsely increased values related to the membrane-associated high-molecular-mass alkaline phosphatase, the manufacturer reformulated the substrate) wash reagent to include a modified, more stable and potent specific inhibitor of human alkaline phosphatase.
Ninety we re-analyzed all the falsely increased samples for which sufficient volume remained: 22 of the 46 falsely increased samples from 10 patients identified by routine screening (Table 3 ) and seven of the 12 patients' samples selected for increased alkaline phosphatase values (Patients 1-7, Table 2 ). The falsely increased values were eliminated in all of the samples selected for alkaline phosphatase content (data not shown) and in 17 of the 22 samples identified by routine screening (Table 3 ). In addition to having CK-MB values <2 g/L when assayed with the anti-TSH antibody-coated tabs, most of the CK-MB values obtained with the new substrate/wash reagent were in agreement with results for the Conan assay. Samples from three patients still gave falsely increased CK-MB results (Table 3) .
Other Potential Interferences
We also examined the influence of other potential interferents. Stratus CK-MB values for samples with increased bilirubin, triglycerides, and creatinine were compared with results obtained by the Conan assay. No interference was found with biirubin, triglycerides, hemoglobin, and creatmine concentrations as great as 0.34, 11.5,4, and 0.22 g/L, respectively.
We also examined a false-positive sample from another automated inmiunometric assay (31). This sample gave a value of 55 g/L in the other CK-MB assay, which decreased to 4 pgfL after 350 pg of mouse IgG c IgO was measured with a sensitive enzyme Immunoassay (27) . d Notdens.
antibody was added to the sample. This indicated that the false-positive value was due to antibodies in the sample that were reactive with murine iminunoglobulin (18). On the Stratus assay, results for this sample were 5.4 and 3.0 pg/L, with and without added mouse immunoglobulin, respectively.
Discussion
Because we measure CK-MB in more than 25000 samples a year we were interested in a less labor-intensive method with a faster turnaround time. The Stratus-CK-MB assay potentially offers these advantages, so we compared it with the Conan CK-MB-specific activity assay. The results from mass and activity assays, based on use of the identical monoclonal antibody, correlated well (r = 0.94), and the precision, linearity, and sensitivity of the mass assay (Stratus assay) were acceptable for routine use. The Stratus assay is free from interferences from commonly encountered interferents. In addition, we found the Stratus assay to be free from interference from anti-murine immunoglobulin in the single sample we examined.
Although both the assays utilized in this report capture CK-MB with the same monoclonal antibody, it was not surprising that the slope of the regression line was not unity because the assays measure different properties of CK-MB. Other studies comparing CK-MB activity assays with mass assays have found similar results (20, 31). For instance, a comparison of the Conan assay with another two-site immunoenzymometric assay (Enzygnost assay; Behring Diagnostics) demonstrated good correlation (r = 0.97; n = 226) with a regression line slope of 0.8 (20) . Another study comparing the Conan assay with another mass concentration assay, but with different CK-MB-and CK-BB-specific monoclonal antibodies, also demonstrated agreement (r = 0.94; n = 1298), with a regression line slope of 0.65 (31). Thus, in addition to the good correlation between the activity and mass assays, the slope of the regression line from this comparison is similar to that of other studies comparing activity and mass assays. Thus, our data, as well as that of others (20, 31) , indicate that mass assays correlate well with activity assays and may be substituted for them after suitable adjustment of the reference range.
During our evaluation we discovered that some samples with increased activity concentrations of alkaline phosphatase had falsely increased CK-MB values in the Stratus assay. Examination of several of these samples by molecular mass sizing chromatography and electrophoresis (26, 30, 32) revealed the presence of a high-molecular-mass form of alkaline phosphatase, presumably from plasma membrane fragments containing several biliary tract enzymes including alkaline phosphatase This form of alkaline phosphatase has been reported to be absent in patients free of cholestatic liver disease but can be found in individuals with cholestasis who have increased or normal concentrations of alkaline phosphatase (25) . A likely explanation for this form of alkaline phosphatase is an electrostatic affinity of this enzyme for the glass-fiber tabs used to capture CK-MB in the Stratus assay. Although an inhibi. tsr of human alkaline phosphatase was present in the original substrate/wash reagent, it may not have been sufficient to inhibit this interferent and its potency may have decreased over time.
When we evaluated a reformulated substrate/wash solution containing a more potent and stable inhibitor of human alkaline phosphatase, CK-MB values obtained were equivalent to those with the old substrate/wash reagent, but the incidence of falsely increased results was dramatically reduced. Also, the new substrate/wash reagent was effective in eliminating the positive interference after four months of storage at 4 #{176}C (data not shown). In the samples from three patients where the interference was not totally eliminated, only one had a clinically significant false-positive CK.MB value with the new reagent. Interestingly, two of these patients had severe liver dysfunction: patient J has received two liver transplants and patient K has been diagnosed as having alcoholic hepatitis. However, patient M is a psychiatric patient with no known liver dysfunction.
Although the falsely increased CK-MB values were associated with a membrane-bound high-molecular-mass alkaline phosphatase, the concentrations of total alkaline phosphatase did not predict whether the interference would be present. For example, in Table 2 , some samples having alkaline phosphatase values as high as 2200 UIL did not have falsely positive CK-MB value, whereas other samples, identified from routine CK-MB requests, were falsely increased for CK-MB with alkaline phosphatase values in the normal range (<115 UIL) ( Table 3) .
We have routinely utilized the Stratus assay for all patients' samples at Barnes Hospital, including those in the coronary care unit for the last eight months. Except for the alkaline phosphatase-related false-positive values, it has performed well and greatly shortened our turnaround time for CK-MB analysis, thereby improving the speed with which the diagnosis of myocardial infarction can be made on serially obtained samples.
